3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
lutetium Lu 177 dotatate
4
3-Iodobenzylguanidine
4
anlotinib
3
gallium Ga 68 dotatate
2
cabozantinib
2
Temozolomide
2
Sunitinib
2
Phenoxybenzamine
2
Magnetic Resonance Spectroscopy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
pembrolizumab
1
olaparib
1
lanreotide
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Vorinostat
1
Specimen Handling
1
Radiosurgery
1
Interleukin-13
1
Genetic Testing
1
Fluorodeoxyglucose F18
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Paraganglioma
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled